Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Western blot [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF630 - Provider product page
- Provider
- R&D Systems
- Product name
- Human TRAIL R3/TNFRSF10C Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human TRAIL R3/TNFRSF10C in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, and rhTRAIL R2 is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
O14798- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells.
Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Wu CH, Kao CH, Safa AR
Human gene therapy 2008 Jul;19(7):731-43
Human gene therapy 2008 Jul;19(7):731-43
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M
International journal of oncology 2007 Dec;31(6):1391-402
International journal of oncology 2007 Dec;31(6):1391-402
Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
Lane D, Côté M, Grondin R, Couture MC, Piché A
Molecular cancer therapeutics 2006 Mar;5(3):509-21
Molecular cancer therapeutics 2006 Mar;5(3):509-21
P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR
Biochemical pharmacology 2006 Jul 28;72(3):293-307
Biochemical pharmacology 2006 Jul 28;72(3):293-307
Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
Roux S, Lambert-Comeau P, Saint-Pierre C, Lépine M, Sawan B, Parent JL
Biochemical and biophysical research communications 2005 Jul 22;333(1):42-50
Biochemical and biophysical research communications 2005 Jul 22;333(1):42-50
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells.
Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P
Circulation research 2003 Apr 18;92(7):732-40
Circulation research 2003 Apr 18;92(7):732-40
Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.
Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR Jr
Cell death and differentiation 2002 Mar;9(3):274-86
Cell death and differentiation 2002 Mar;9(3):274-86
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC
Oncogene 2002 Aug 22;21(37):5673-83
Oncogene 2002 Aug 22;21(37):5673-83
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Detection of Human TRAIL R3/TNFRSF10C by Western Blot. Western blot shows lysates of L-929 mouse fibroblast cell line, THP-1 human acute monocytic leukemia cell line, and WS-1 human fetal skin fibroblast cell line. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Human TRAIL R3/TNFRSF10C Antigen Affinity-purified Polyclonal Antibody (Catalog # AF630) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for TRAIL R3/TNFRSF10C at approximately 27 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- TRAIL R3/TNFRSF10C Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R3/TNFRSF10C Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (5 µg/mL, Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (Catalog # 630-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/ TNFSF10 (12 ng/mL) activity elicited by Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TRAIL R3/ TNFRSF10C Antigen Affinity-purified Polyclonal Antibody (Catalog # AF630). The ND50 is typically 0.015-0.045 µg/mL.
